11.05.26 -- Your CDMO Quality Dashboard Is Green. What's It Hiding?

Within the past few decades, there has been a steady increase in the use of pre-filled syringes (PFS) for parenteral administration of biologics, biosimilars, and other drugs.

ADC success depends less on molecular design than on a continuous analytical strategy that connects early characterization to late-stage control, preventing variability, data gaps, and regulatory issues.

Lyophilization ensures product stability, extends shelf life, supports sensitive formulations, and simplifies storage and transport, making it a critical choice for modern drug development projects.

Controlling reagent variability across formulation and manufacturing is critical to maintaining consistent performance as processes scale from research to production.

Moving innovative science toward patients requires more than a promising laboratory result. Explore how nanoparticles and advanced drug development technologies are translated into practical solutions.

At roughly 600,000 samples per year, manual EM documentation creates real compliance and operational risk. This whitepaper details how a fully integrated digital sampling system addresses both.

Delve into how cloud-based systems and unified data platforms are transforming biomanufacturing by enhancing efficiency, ensuring quality, and accelerating the delivery of complex therapies to market.

In our series on pre-filled syringes, we explore five key ways this delivery format is enhancing patient outcomes, not just through the medicine it contains, but through the device design itself.

These real-world case studies highlight best practices and strategies to optimize bioconjugate drug product tech transfers and supplies in the clinical or commercial phase.

Learn how single-pass tangential flow approaches improve efficiency, scalability, and product quality while addressing key development and processing challenges.

Find out how reducing vendor fragmentation can improve program continuity, minimize delays, and support more predictable development outcomes.

As biologics manufacturing globalizes, companies must balance cost, capacity, risk, and control when choosing between European and Asian supply bases for clinical and commercial success.

Nanoparticle engineering enabled a 440 mg/mL trastuzumab suspension that clears viscosity and stability barriers limiting conventional high-dose subcutaneous biologics formulations.